CancerDrs

Lung Cancer clinical trials in Texas

132 actively recruiting lung cancer trials at 53 sites across Texas.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 3 Recruiting NIH

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Sites in Texas:
  • Hendrick Medical Center — Abilene, Texas
  • The Don and Sybil Harrington Cancer Center — Amarillo, Texas
  • Dell Seton Medical Center at The University of Texas — Austin, Texas
  • Houston Methodist San Jacinto Hospital — Baytown, Texas
  • Saint Joseph Regional Cancer Center — Bryan, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…

Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Texas:
  • MD Anderson in The Woodlands — Conroe, Texas
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
  • Ben Taub General Hospital — Houston, Texas
  • M D Anderson Cancer Center — Houston, Texas
  • MD Anderson West Houston — Houston, Texas
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Texas:
  • Local Institution - 007-554B — Abilene, Texas
  • Local Institution - 007-554G — Amarillo, Texas
  • Local Institution - 007-879-A — Arlington, Texas
  • Local Institution - 007-879-B — Arlington, Texas
  • Local Institution - 007-892-B — Austin, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…

Sponsor: Pfizer
NCT ID: NCT07222566
Sites in Texas:
  • Texas Oncology - West Texas — Abilene, Texas
  • Texas Oncology - Northeast Texas — Allen, Texas
  • Texas Oncology - West Texas — Amarillo, Texas
  • Texas Oncology - DFW — Arlington, Texas
  • Texas Oncology - DFW — Arlington, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …

Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in Texas:
  • USO - Texas Oncology — Austin, Texas
  • William Beaumont Army Medical Center — Fort Bliss, Texas
  • Houston Methodist Hospital — Houston, Texas
  • University of Texas MD Anderson Cancer Center — Houston, Texas
  • USO - Texas Oncology — Webster, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in Texas:
  • Clinical Study Site — Abilene, Texas
  • Clinical Study Site — Austin, Texas
  • Clinical Study Site — Dallas, Texas
  • Clinical Study Site — Forth Worth, Texas
  • Clinical Study Site — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…

Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in Texas:
  • The Center for Cancer and Blood Disorders — Fort Worth, Texas
  • Houston Methodist Hospital — Houston, Texas
  • University of Texas MD Anderson Cancer Center — Houston, Texas
  • USO - Texas Oncology - San Antonio — San Antonio, Texas
  • USO - Texas Oncology Gulf Coast — Sugar Land, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary en…

Sponsor: Summit Therapeutics
NCT ID: NCT05899608
Sites in Texas:
  • Texas Oncology- Austin — Austin, Texas
  • Texas Oncology-Dallas — Dallas, Texas
  • UT Southwestern Medical Center — Dallas, Texas
  • Houston Methodist Hospital — Houston, Texas
  • MD Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Sites in Texas:
  • Local Institution - 0034 — Dallas, Texas
  • Local Institution - 0692 — Galveston, Texas
  • Local Institution - 0652 — Laredo, Texas
  • Texas Oncology - San Antonio — San Antonio, Texas
  • Local Institution - 0700 — Tyler, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in Texas:
  • Texas Oncology - DFW ( Site 8103) — Dallas, Texas
  • UT Southwestern Medical Center ( Site 0190) — Dallas, Texas
  • Houston Methodist Cancer Center ( Site 0191) — Houston, Texas
  • MD Anderson Cancer Center ( Site 0150) — Houston, Texas
  • Memorial Hermann Cancer Center ( Site 0172) — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in Texas:
  • Texas Oncology - West Texas — Abilene, Texas
  • Local Institution - 0305 — Harlingen, Texas
  • University of Texas MD Anderson Cancer Center — Houston, Texas
  • The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center — Tyler, Texas
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemot…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07063745
Sites in Texas:
  • Local Institution - 0433 — Dallas, Texas
  • Renovatio Clinical - El Paso — El Paso, Texas
  • University of Texas MD Anderson Cancer Center — Houston, Texas
  • Local Institution - 0377 — The Woodlands, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…

Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in Texas:
  • Baylor Scott and White Research Institute (Adults only) — Dallas, Texas
  • University of Texas Southwestern Medical Center - Children's Medical Center (Pediatrics only) — Dallas, Texas
  • MD Anderson Cancer Center (Pediatrics and Adult) — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.

Sponsor: AstraZeneca
NCT ID: NCT06868277
Sites in Texas:
  • Research Site — Round Rock, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Long-term Extension Study of PCI-32765 (Ibrutinib)

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in Texas:
  • MD Anderson Cancer Center - University of Texas — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation thera…

Sponsor: Shanghai Junshi Bioscience Co., Ltd.
NCT ID: NCT06095583
Sites in Texas:
  • Millennium Physicians - Oncology — Houston, Texas
  • Texas Oncology, P.A. - Oncology — Tyler, Texas
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has …

Sponsor: Pfizer
NCT ID: NCT07226999
Sites in Texas:
  • Texas Oncology - Gulf Coast — Beaumont, Texas
  • Texas Oncology - San Antonio — Fredericksburg, Texas
  • Texas Oncology - Gulf Coast — Houston, Texas
  • Texas Oncology - Gulf Coast — Houston, Texas
  • Texas Oncology - San Antonio — New Braunfels, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants …

Sponsor: ArriVent BioPharma, Inc.
NCT ID: NCT07185997
Sites in Texas:
  • Texas Oncology — Dallas, Texas
  • The University of Texas MD Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

The purpose of this phase 3 multicenter double-blind randomized study is to assess the use of taletrectinib in the early-stage non-small cell lung cancer (NSCLC). The study compares taletrectinib (study drug) versus placebo (sugar pill) in…

Sponsor: Nuvation Bio Inc.
NCT ID: NCT07154706
Sites in Texas:
  • Sarah Cannon Research Institute (SCRI) - Texas Oncology-Central South — Austin, Texas
  • MD Anderson — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging …

Sponsor: Vergent Bioscience, Inc.
NCT ID: NCT07499674
Sites in Texas:
  • University of Texas, MD Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places i…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06031688
Sites in Texas:
  • The Don and Sybil Harrington Cancer Center — Amarillo, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-smal…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06667076
Sites in Texas:
  • Texas Oncology South — Austin, Texas
  • Parkland Health and Hospital System — Dallas, Texas
  • Texas Oncology DFW — Dallas, Texas
  • UT Southwestern Medical Center — Dallas, Texas
  • Renovatio Clinical — El Paso, Texas
View on ClinicalTrials.gov →

Showing 25 of 132 trials with sites in Texas. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15